Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SuperGen has dosed the first patient in its phase I clinical trial of its oral, multi-targeted tyrosine kinase inhibitor. The trial is expected to enroll up to 30 patients with advanced-stage solid tumors at two study centers.
Subscribe to our email newsletter
The phase I trial is an accelerated titration dose-escalation study designed to assess the safety and tolerability of MP470, and to determine the maximum tolerated dose of the compound in patients with advanced-stage solid tumors.
Additionally, the company will assess pharmacokinetic and biomarker data from the study to assist in designing follow-on clinical studies for the use of MP470 as a single agent and in combination treatment modalities.
“We will continue to advance novel compounds for cancer patients into clinical development, furthering our transition to an integrated discovery and development organization,” said Dr Gregory Berk, chief medical officer of SuperGen.